Organogenesis (ORGO) Projected to Post Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Organogenesis to post earnings of ($0.03) per share and revenue of $90.77 million for the quarter.

Organogenesis Stock Performance

Shares of ORGO stock opened at $5.32 on Tuesday. The firm has a market cap of $674.86 million, a price-to-earnings ratio of -88.67 and a beta of 1.85. Organogenesis has a 52-week low of $2.21 and a 52-week high of $7.50. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average is $4.67 and its 200 day moving average is $3.86.

Insider Transactions at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares of the company’s stock, valued at $851,082.90. This represents a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 36.90% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley boosted their price target on Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.